Special Issues

  • HOME
  • Special Issues
  • Special issue
Recent update on therapeutics for NAFLD

Topic: Recent update on therapeutics for NAFLD

Guest Editor: Won Kim, M.D.
Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center

Special Issue Introduction
Nonalcoholic steatohepatitis (NASH) is a major unmet health need and a significant, growing cause of chronic liver disease with an ever-increasing toll on cirrhosis, hepatocellular carcinoma, and liver transplantation. In this context, both academic and industrial communities are bringing global attention to the treatment of NASH requiring a holistic approach. The current special issue aims to review the most recent preclinical and clinical investigations, and promote the rapid emergence of novel and efficient therapeutic approaches.

Submission Information
For Special issue guidelines, please refer to https://www.e-cmh.org/special/guidelines.php
For Author Instructions, please refer to https://www.e-cmh.org/authors/authors.php
For Online Submission, please login at https://mc04.manuscriptcentral.com/cmh
Contacts: Han Ah Lee, Associate editor, amelia86@naver.com

Original Article
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim
Clin Mol Hepatol. 2022;28(3):497-509.   Published online April 28, 2022

Clinical and

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
TODAY : 1242
TOTAL : 1128364
Close layer